Article Text

Download PDFPDF
Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

OpenUrlCrossRefPubMedWeb of Science

Q What are the effects of risperidone, olanzapine, quetiapine, and ziprasidone on time to discontinuation in people who have discontinued another atypical antipsychotic?


Embedded ImageDesign:

Randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

Double blind.

Embedded ImageFollow up period:

Eighteen months.

Embedded ImageSetting:

Fifty seven clinical sites, USA; from January 2001 to December 2004.

Embedded ImagePatients:

333 people aged between 16 and 65 years with schizophrenia (DSM-IV; mean age 40.8 years; 69% male) who discontinued treatment with the assigned atypical antipsychotic in the first phase of the study (for any reason). Exclusions: prior resistance to study drugs or treatment with clozapine for resistance; history of serious adverse reaction to study drugs; first episode schizophrenia; schizoaffective disorder; mental retardation; cognitive disorder; pregnant; breast feeding; or serious medical comorbidity.

Embedded ImageIntervention:

Olanzapine (7.5–30 mg/day); quetiapine (200–800 mg/day); risperidone (1.5–6 mg/day); …

View Full Text


  • For correspondence: Dr T Scott Stroup, department of Psychiatry, University of North Carolina at Chapel Hill, CB# 7160, Chapel Hill, NC 27599-7160, USA; sstroup{at}

  • Source of funding: National Institute of Mental Health, USA.